- Home
- VET vs IBRX Comparison
VET vs IBRX Comparison
Compare VET & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VET
- IBRX
- Stock Information
- Founded
- VET 1994
- IBRX 2014
- Country
- VET Canada
- IBRX United States
- Employees
- VET N/A
- IBRX N/A
- Industry
- VET Oil & Gas Production
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VET Energy
- IBRX Health Care
- Exchange
- VET Nasdaq
- IBRX Nasdaq
- Market Cap
- VET 1.6B
- IBRX 1.9B
- IPO Year
- VET N/A
- IBRX N/A
- Fundamental
- Price
- VET $10.13
- IBRX $2.94
- Analyst Decision
- VET
- IBRX Strong Buy
- Analyst Count
- VET 0
- IBRX 3
- Target Price
- VET N/A
- IBRX $13.58
- AVG Volume (30 Days)
- VET 1.3M
- IBRX 6.3M
- Earning Date
- VET 03-05-2025
- IBRX 11-12-2024
- Dividend Yield
- VET 3.41%
- IBRX N/A
- EPS Growth
- VET N/A
- IBRX N/A
- EPS
- VET N/A
- IBRX N/A
- Revenue
- VET $1,344,960,953.00
- IBRX $7,332,000.00
- Revenue This Year
- VET $13.28
- IBRX $2,515.60
- Revenue Next Year
- VET $7.62
- IBRX $766.19
- P/E Ratio
- VET N/A
- IBRX N/A
- Revenue Growth
- VET N/A
- IBRX 1218.71
- 52 Week Low
- VET $8.22
- IBRX $2.28
- 52 Week High
- VET $12.79
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- VET 59.49
- IBRX 48.30
- Support Level
- VET $10.07
- IBRX $2.28
- Resistance Level
- VET $10.47
- IBRX $2.54
- Average True Range (ATR)
- VET 0.27
- IBRX 0.25
- MACD
- VET 0.08
- IBRX 0.10
- Stochastic Oscillator
- VET 78.27
- IBRX 64.71
About VET Vermilion Energy Inc. Common (Canada)
Vermilion Energy Inc is an international oil and gas-producing company. It engages in full-cycle exploration and production programs that focus on the acquisition, exploration, development, and optimization of producing properties in North America, Europe, and Australia. The majority of Vermilion's revenue is derived from the production and sale of petroleum and natural gas. In each market, the company relies on a host of drilling and well-completion techniques to keep production at attractive levels. It derives a majority of its revenue from Canada.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.